38 studies found for:    " January 02, 2013":" February 01, 2013"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" January 02, 2013":" February 01, 2013"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: Placebo to match E/C/F/TDF;   Drug: Placebo to match E/C/F/TAF
2 Not yet recruiting Steady State PK in Malnourished HIV Infected Children
Conditions: HIV Positive;   Malnourished
Intervention: Drug: ZDV+3TC+LPV/r
3 Completed Folinic Acid and Vascular Reactivity in HIV
Condition: Human Immunodeficiency Virus (HIV) Infection
Interventions: Dietary Supplement: Folinic Acid;   Other: Placebo
4 Recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
Conditions: HIV Infection;   HIV-associated Hodgkin Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage IV Adult Hodgkin Lymphoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: vinblastine;   Drug: dacarbazine;   Drug: brentuximab vedotin;   Other: pharmacological study;   Other: laboratory biomarker analysis
5 Active, not recruiting Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers
Conditions: Heavy Drinking;   HIV;   Alcohol Dependence
Interventions: Drug: Topiramate;   Behavioral: Medical Management
6 Active, not recruiting Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).
Condition: HIV Infection
Intervention: Drug: FTC/TDF (Truvada®)
7 Recruiting An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)
Condition: HIV Infection
Interventions: Behavioral: 3MV;   Behavioral: PCC;   Drug: Emtricitabine/tenofovir (FTC/TDF (Truvada®))
8 Recruiting A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services
Condition: HIV Prevention
Intervention: Drug: emtricitabine 200mg/tenofovir 300mg
9 Recruiting Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy
Condition: Human Immunodeficiency Virus
Interventions: Drug: Raltegravir;   Drug: Fluconazole;   Drug: Azithromycin;   Drug: Albendazole;   Drug: Isoniazid;   Dietary Supplement: Ready to Use Supplementary Food
10 Active, not recruiting An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Continued Access Arm
11 Recruiting Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at High Risk of Acquiring HIV-1 Infection
Condition: HIV Infections
Intervention: Drug: Raltegravir
12 Completed Feasibility of Using a Structured Daily Diary
Condition: HIV Infection
Intervention: Behavioral: Structured daily diary
13 Active, not recruiting Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: NYVAC-HIV-PT1 vaccine;   Biological: NYVAC-HIV-PT4 vaccine;   Biological: Placebo for DNA-HIV-PT123 vaccine;   Biological: Placebo for NYVAC-HIV-PT1 vaccine;   Biological: Placebo for NYVAC-HIV-PT4 vaccine
14 Not yet recruiting Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I AIDS-related Lymphoma;   Stage II AIDS-related Lymphoma;   Stage III AIDS-related Lymphoma;   Stage IV AIDS-related Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: carmustine;   Drug: cytarabine;   Drug: melphalan;   Drug: etoposide;   Drug: O6-benzylguanine;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
15 Completed Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting
Condition: HIV-1 Infection
Interventions: Drug: nevirapine;   Drug: ritonavir-boosted Lopinavir;   Drug: Tenofovir/emtricitabine;   Drug: Zidovudine/lamivudine
16 Recruiting FTC/RPV/TDF on T-Cell Activation, CD4 Cell Count, Inflammatory Biomarkers and Viral Reservoir
Condition: HIV-1 Infection
Intervention: Drug: Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
17 Recruiting Mater-Bronx Rapid HIV Testing Project.
Condition: Human Immunodeficiency Virus
Interventions: Other: No participant choice of counselor;   Other: Participant choice of counselor
18 Completed A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects
Conditions: Chronic Hepatitis C;   Human Immunodeficiency Virus
Interventions: Drug: Sofosbuvir;   Drug: RBV
19 Recruiting Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients
Condition: HIV
Intervention:
20 Active, not recruiting Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)
Conditions: Chronic Obstructive Pulmonary Disease;   HIV
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-38) Show next page of results
Indicates status has not been verified in more than two years